The findings from a small clinical trial in Nature Medicine found that some people with non-Hodgkin lymphoma (NHL), treating a single tumor with a mix of cancer therapies can help to shrink, or eliminate, tumors in other parts of the body. The approach is called an in situ vaccine because it uses something in the body (in situ)—in this case, an individual tumor—to help create a body-wide immune response. It’s currently being tested in a small clinical trial of patients with slow-growing, or indolent, subtypes of NHL.
To read more on this clinical trial, click here.
No comments:
Post a Comment